

In the Specification:

Please amend the specification as shown:

Please delete the paragraphs on page 13, line 1 to page 15, line 23 and replace them with the following paragraphs:

Figure 15. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a-p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rqgkrlrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgkrlrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 2.5 μ g/ml, peptides were used at 750 μ M final concentration for each peptide, and each data point is the mean of two independent assays

Figure 16. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (26%); c, svpFWVrms peptide (SEQ ID NO: 9) (64%); d, tRwATSRit peptide (SEQ ID NO: 10) (58%); e, aWssLahcl peptide (SEQ ID NO: 11) (50%); f, rqgkrlrgp peptide (SEQ ID NO: 13) (105%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (52%); h,

svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (43%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (41%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgkrlrgp peptide (SEQ ID NO: 13) (59%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13) (55%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13) (46%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13) (49%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13) (42%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13) (40%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (42%). Human ICAM-4Fc was coated at a concentration of 2.5 μ g/ml, peptides were used at 750 μ M final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 17. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a -p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rqgkrlrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgkrlrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgkrlrgp peptide (SEQ ID NO: 13), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgkrlrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 5 μ g/ml, peptides were used at 750 μ M final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 18. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (10%); c, svpFWVrms peptide (SEQ ID NO: 9) (41%); d, tRwATSRit peptide (SEQ ID NO: 10) (42%); e, aWssLahcl peptide (SEQ ID NO: 11) (71%); f, rqgktlrgp peptide (SEQ ID NO: 13) (96%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (46%); h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (52%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (50%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktlrgp peptide (SEQ ID NO: 13) (40%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktlrgp peptide (SEQ ID NO: 13) (39%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktlrgp peptide (SEQ ID NO: 13) (64%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktlrgp peptide (**SEQ ID NO: 13**) (39%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktlrgp peptide (SEQ ID NO: 13) (50%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktlrgp peptide (SEQ ID NO: 13) (48%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (52%). Human ICAM-4Fc was coated at a concentration of 5 μ g/ml, peptides were used at 750 μ M final concentration for each peptide, and each data point is the mean of two independent assays.

Please delete the paragraph on page 26, line 1 to page 27 line 34 and replace it with the following paragraph:

SEQ ID NOS: 40 and 1 – Combined nucleotide (SEQ ID NO: 40) and amino acid (SEQ ID NO: 41) sequence of mature human ICAM-4

1

20

A Q S P K G S P L A P S G T S V P F W V
GCGCAAAGCCCCAAGGGTAGCCCTCTCGCGCCCTCCGGGACCTCAGTGCCCTCTGGGTG

101

160

21 40
R M S P E F V A V Q P G K S V Q L N C S
CGCATGAGCCGGAGTCGTGGCTGTGCAGCCGGGAAGTCAGTGCAGCTCAATTGCAGC
161 220

41 60
N S C P Q P Q N S S L R T P L R Q G K T
AACAGCTGTCCCCAGCCGAGAATTCCAGCCTCCGCACCCGCTGCCGAAAGGCAAGACG
221 280

61 80
L R G P G W V S Y Q L L D V R A W S S L
CTCAGAGGGCCGGGTTGGGTGTCTTACCAGCTGCTCGACGTGAGGGCTGGAGCTCCCTC
281 340

81 100
A H C L V T C A G K T R W A T S R I T A
GCGCACTGCCTCGTGACCTGCCAGGAAAAACACGCTGGCCACCTCCAGGATCACCGCC
341 400

101 120
Y K P P H S V I L E P P V L K G R K Y T
TACAAACCGCCCCACAGCGTGATTTGGAGCCTCCGGTCTTAAAGGGCAGGAAAATAACT
401 460

121 140
L R C H V T Q V F P V G Y L V V T L R H
TTGCGCTGCCACGTGACGCAGGTGTTCCGGTGGCTACTGGTGGTACCCGAGGCAT
461 520

141 160
G S R V I Y S E S L E R F T G L D L A N
GGAAGCCGGGTCATCTATTCCAAAGCCTGGAGCGCTTCACCGCCCTGGATCTGGCCAAAC
521 580

161 180

V T L T Y E F A A G P R D F W Q P V I C
GTGACCTTGACCTACGAGTTGCTGCTGGACCCCGCAGACTTCTGGCAGCCCGTGATCTGC
581 640

H A R L N L D G L V V R N S S A P I T L
CACGCGCGCCTCAATCTGACGGCCTGGTGGTCCGCAACAGCTCGGCACCCATTACACTG
641 700

M L A W S P A P T A L A S G S I A A L V
ATGCTCGCTTGGAGCCCCGCGCCCACAGCTTGGCCTCCGGTTCCATCGCTGCCCTTGTA
701 760

G I L L T V G A A Y L C K C L A M K S Q
GGGATCCTCCTCACTGTGGCGCTGCGTACCTATGCAAGTGCCTAGCTATGAAGTCCCAG
761 820

A
GCG
821-823

Underlined and in bold are the mutated residues which comprise the footprint (F18, W19, V20, R92, A94, T95, S96, R97, T91, R52, E151, T154, W93, L80, W77).

In bold and in italics are the "super-adhesive" residues involved in the N-glycosylation site (N160 and T162).

W66 and K118 are shown in bold alone.